Efficacy of the topic RV3131A-HC3221 in the prevention of polymorphic light eruption

Efficacy of the topic RV3131A-HC3221 in the prevention of polymorphic light eruption

Hide study title

Status

Status :

Completed

Type of study

Phase II

Min. Age

18

Years old

Max. Age

64

Years old

Gender

All

Therapeutic area :

Dermatology

Disease :

Polymorphic light eruption

Study medication :

Rv313

Phase : Phase II

Start Date :

28 September 2004

End date :

14 February 2006

Study ID : V00096 CR 201

EudraCT/CTIS number : 2004-001241-14

Results

Public links :

EU Clinical Trials Register